赵 营,赵光日,吴蕴瑜,吕晓刚,黄高延.子宫内膜癌组织残疾基因同源物2、核连蛋白-2、黏蛋白4的表达及与预后的关系研究[J].,2021,(4):754-758 |
子宫内膜癌组织残疾基因同源物2、核连蛋白-2、黏蛋白4的表达及与预后的关系研究 |
Expression of Disabled Gene Homologue 2, Nucleoctonin-2 and MUC4 in Endometrial Carcinoma and Its Relationship with Prognosis |
投稿时间:2020-09-23 修订日期:2020-10-18 |
DOI:10.13241/j.cnki.pmb.2021.04.033 |
中文关键词: 子宫内膜癌 残疾基因同源物2 核连蛋白-2 黏蛋白4 预后 |
英文关键词: Endometrial carcinoma Disability gene homologue 2 Nucleobindin-2 MUC4 Prognosis |
基金项目:广东省医学科研基金项目(B20150152) |
|
摘要点击次数: 855 |
全文下载次数: 487 |
中文摘要: |
摘要 目的:研究子宫内膜癌组织残疾基因同源物2(DAB2)、核连蛋白-2(nucleobindin-2)、黏蛋白4(MUC4)的表达及与预后的关系。方法:将我院从2015年1月~2017年1月收治的子宫内膜癌患者82例纳入研究。分别采集所有患者的子宫内膜癌组织以及癌旁正常组织,以免疫组化法检测不同子宫内膜组织中的DAB2、nucleobindin-2、MUC4表达情况并进行对比。分析子宫内膜癌组织DAB2、nucleobindin-2、MUC4阳性率与临床病理特征的关系。此外,通过Kaplan-Merier生存曲线分析上述蛋白表达与预后的关系,并以Cox比例风险回归模型分析子宫内膜癌患者预后的影响因素。结果:子宫内膜癌组织DAB2阳性率低于癌旁正常组织,而nucleobindin-2、MUC4阳性率均高于癌旁正常组织(均P<0.05)。TNM分期Ⅲ~Ⅳ期、淋巴结转移子宫内膜癌患者的DAB2阳性率低于TNM分期Ⅰ~Ⅱ期、无淋巴结转移患者,而nucleobindin-2、MUC4阳性率均高于TNM分期Ⅰ~Ⅱ期、无淋巴结转移患者(均P<0.05)。所有患者均进行时长3~60个月的随访,中位随访时间为31个月,至随访结束,DAB2蛋白阳性患者的无进展生存率分别为66.67%(20/30),明显高于DAB2蛋白阴性患者的19.23%(10/52);而nucleobindin-2、MUC4蛋白阳性患者的无进展生存率分别为22.95%(14/61)、24.56%(14/57),明显低于nucleobindin-2、MUC4蛋白阴性患者的76.19%(16/21)、64.00%(16/25),差异均有统计学意义(均P<0.05)。Cox比例风险回归模型分析结果可得:TNM分期、淋巴结转移以及DAB2蛋白阴性、nucleobindin-2蛋白阳性、MUC4蛋白阳性均是子宫内膜癌患者预后的影响因素(均P<0.05)。结论:子宫内膜癌组织DAB2存在异常低表达,而nucleobindin-2、MUC4均存在异常高表达,联合检测上述三项蛋白表达情况可能有助于子宫内膜癌的诊断和预后评估。 |
英文摘要: |
ABSTRACT Objective: To study the expression of disabled gene homologue 2(DAB2), nucleobindin-2 (nucleobindin-2) and MUC4 (MUC4) in endometrial carcinoma tissues and its relationship with prognosis. Methods: A total of 82 patients with endometrial cancer who were admitted to our hospital from January 2015 to January 2017 were included in this study. Endometrial cancer tissues and adjacent normal tissues of all patients were collected respectively, and the expressions of DAB2, nucleobindin-2 and MUC4 in different endometrial tissues were detected by immunohistochemistry and compared. The relationship between the positive rates of DAB2, nucleobindin-2, MUC4 and clinicopathological features of endometrial carcinoma were analyzed. In addition, Kaplan-Merier survival curve was used to analyze the relationship between the expression of the above proteins and prognosis, and Cox regression model was used to analyze the risk factors affecting the prognosis of patients with endometrial cancer. Results: The positive rate of DAB2 in endometrial carcinoma was lower than that in adjacent normal tissues, while the positive rates of nucleobindin-2 and MUC4 were higher than those in adjacent normal tissues (all P<0.05). TNM staging Ⅲ ~ Ⅳ stage, patients with lymph node metastasis of endometrial carcinoma of DAB2 positive rate was lower than the TNM staging Ⅰ~Ⅱ stage, patients with no lymph node metastasis, while the nucleobindin - 2, MUC4 positive rate were higher than TNM staging Ⅰ~Ⅱ stage, patients with no lymph node metastasis (all P<0.05). All subjects were followed up for 3-60 months, with a median follow-up time of 31 months. At the end of the follow-up, the progression-free survival rate of patients with DAB2 protein positive was 66.67%(20/30), which was significantly higher than that of patients with DAB2 protein negative of 19.23%(10/52). The progression-free survival rates of nucleobindin-2 and MUC4 protein positive patients were 22.95% (14/61) and 24.56% (14/57), which were significantly lower than those of 76.19% (16/21) and 64.00% (16/25) in nucleobindin-2 and MUC4 protein negative patients, the differences were statistically significant (all P<0.05). The results of Cox proportional risk regression model showed that TNM stage, lymph node metastasis, DAB2 negative protein, nucleobindin-2 positive protein and MUC4 positive protein were all risk factors for the prognosis of patients with endometrial cancer (all P<0.05). Conclusion: Abnormal low expression of DAB2 and abnormally high expression of nucleobindin-2 and MUC4 in endometrial cancer tissue. Combined detection of the expression of the above three proteins may be helpful for the diagnosis and prognosis evaluation of endometrial cancer. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|